Contact
searchSearch
HMP Global
Login

Multiple Myeloma Specialty Channel

Multiple Myeloma
Specialty Channel
News
Mezigdomide Plus Carfilzomib and Dexamethasone Improves PFS in R/R Multiple Myeloma
03/11/2026
Stephanie Holland
Interim results from the phase 3 SUCCESSOR-2 trial demonstrate that mezigdomide plus carfilzomib and dexamethasone significantly improved PFS in patients with relapsed/refractory multiple myeloma versus carfilzomib and dexamethasone alone.
Interim results from the phase 3 SUCCESSOR-2 trial demonstrate that mezigdomide plus carfilzomib and dexamethasone significantly improved PFS in patients with relapsed/refractory multiple myeloma versus carfilzomib and dexamethasone alone.
Interim results from the phase 3...
03/11/2026
Oncology
FDA Approval
FDA Approves Teclistamab Plus Daratumumab Hyaluronidase for Relapsed or Refractory Multiple Myeloma
03/05/2026
Emily Estrada
Based on results from the phase 3 MajesTEC-3 trial, the FDA approved teclistamab plus daratumumab hyaluronidase for previously treated patients with relapsed or refractory multiple myeloma.
Based on results from the phase 3 MajesTEC-3 trial, the FDA approved teclistamab plus daratumumab hyaluronidase for previously treated patients with relapsed or refractory multiple myeloma.
Based on results from the phase...
03/05/2026
Oncology
Quiz
Oral Iberdomide Combination for R/R MM
02/24/2026
Test your knowledge on the safety profile of oral iberdomide plus low-dose cyclophosphamide and dexamethasone for patents with R/R multiple myeloma.
Test your knowledge on the safety profile of oral iberdomide plus low-dose cyclophosphamide and dexamethasone for patents with R/R multiple myeloma.
Test your knowledge on the...
02/24/2026
Oncology
FDA Approval
FDA Grants Approval to Daratumumab and Hyaluronidase With Bortezomib, Lenalidomide, and Dexamethasone for Newly Diagnosed MM
01/27/2026
Gina Tomaine
On January 27, 2026, the FDA granted approval to daratumumab and hyaluronidase-fihj in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for patients with newly diagnosed multiple myeloma who are ineligible for autologous...
On January 27, 2026, the FDA granted approval to daratumumab and hyaluronidase-fihj in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for patients with newly diagnosed multiple myeloma who are ineligible for autologous...
On January 27, 2026, the FDA...
01/27/2026
Oncology
News
FDA Issues Draft Guidance on Use of MRD and Complete Response as End Points to Support Accelerated Approval in Multiple Myeloma
01/20/2026
Emily Estrada
On January 20, 2026, the FDA issued guidance outlining recommendations for the use of minimal residual disease and complete response as primary end points to support accelerated approval of drugs and biologics for the treatment of multiple...
On January 20, 2026, the FDA issued guidance outlining recommendations for the use of minimal residual disease and complete response as primary end points to support accelerated approval of drugs and biologics for the treatment of multiple...
On January 20, 2026, the FDA...
01/20/2026
Oncology
News
Oral Iberdomide Combination Demonstrates Clinically Meaningful Activity for R/R Multiple Myeloma
01/14/2026
Emily Estrada
The all-oral combination of iberdomide, cyclophosphamide, and dexamethasone (IberCd) demonstrated a median progression-free survival and manageable safety in patients with R/R multiple myeloma previously exposed to multiple drug classes.
The all-oral combination of iberdomide, cyclophosphamide, and dexamethasone (IberCd) demonstrated a median progression-free survival and manageable safety in patients with R/R multiple myeloma previously exposed to multiple drug classes.
The all-oral combination of...
01/14/2026
Oncology
Conference Coverage
Belantamab Mafodotin Triplet for R/R MM Shows Sustained Superiority vs Pomalidomide, Bortezomib, and Dexamethasone: DREAMM-8 Long-Term Follow-Up
12/07/2025
Gina Tomaine
Deep responses and durable outcomes were demonstrated among patients treated with belantamab mafodotin plus pomalidomide and dexamethasone from long-term follow-up of the phase 3 DREAMM-8 study presented at the 2025 ASH Annual Meeting.
Deep responses and durable outcomes were demonstrated among patients treated with belantamab mafodotin plus pomalidomide and dexamethasone from long-term follow-up of the phase 3 DREAMM-8 study presented at the 2025 ASH Annual Meeting.
Deep responses and durable...
12/07/2025
Oncology
Conference Coverage
Outcomes of Cilta-Cel Manufacturing for Lenalidomide-Refractory Multiple Myeloma Strongly Influenced by Prior Lines of Therapy
12/06/2025
Emily Estrada
The success of ciltacabtagene autoleucel manufacturing for patients with lenalidomide-refractory MM as early as first relapse decreases with more prior lines of therapy, according to data presented at the 2025 ASH Annual Meeting & Exposition.
The success of ciltacabtagene autoleucel manufacturing for patients with lenalidomide-refractory MM as early as first relapse decreases with more prior lines of therapy, according to data presented at the 2025 ASH Annual Meeting & Exposition.
The success of ciltacabtagene...
12/06/2025
Oncology
Conference Coverage
Talquetamab Plus Teclistamab Demonstrates Durable Efficacy for Patients With R/R MM and Extramedullary Disease: Updated Results from RedirecTT-1 Study
12/06/2025
Emily Estrada
Talquetamab plus teclistamab achieved high response rates for patients with relapsed/refractory multiple myeloma and true extramedullary disease, according to longer follow-up, phase 2 results presented at the 2025 ASH Annual Meeting &...
Talquetamab plus teclistamab achieved high response rates for patients with relapsed/refractory multiple myeloma and true extramedullary disease, according to longer follow-up, phase 2 results presented at the 2025 ASH Annual Meeting &...
Talquetamab plus teclistamab...
12/06/2025
Oncology
Conference Coverage
Identifying Key Predictors of Early Relapse After Treatment With Ciltacabtagene Autoleucel to Inform Risk-Adapted Strategies for Patients With R/R MM
12/06/2025
Emily Estrada
A multicenter analysis presented at the 2025 ASH Annual Meeting identified key predictors of relapse within 18 months of ciltacabtagene autoleucel infusion to improve treatment strategy for patients with high-risk relapsed/refractory multiple...
A multicenter analysis presented at the 2025 ASH Annual Meeting identified key predictors of relapse within 18 months of ciltacabtagene autoleucel infusion to improve treatment strategy for patients with high-risk relapsed/refractory multiple...
A multicenter analysis presented...
12/06/2025
Oncology
Conference Coverage
Cilta-Cel Demonstrates Deep and Durable Responses for Standard-Risk Relapsed/Refractory Myeloma: CARTITUDE-4 Subgroup Analysis
12/06/2025
Emily Estrada
Based on results from the CARTITUDE-4 study presented at the 2025 ASH Annual Meeting, a ciltacabtagene autoleucel infusion achieved durable responses and promising survival outcomes for standard-risk relapsed/refractory multiple myeloma.
Based on results from the CARTITUDE-4 study presented at the 2025 ASH Annual Meeting, a ciltacabtagene autoleucel infusion achieved durable responses and promising survival outcomes for standard-risk relapsed/refractory multiple myeloma.
Based on results from the...
12/06/2025
Oncology

News

News
Mezigdomide Plus Carfilzomib and Dexamethasone Improves PFS in R/R Multiple Myeloma
03/11/2026
Stephanie Holland
Interim results from the phase 3 SUCCESSOR-2 trial demonstrate that mezigdomide plus carfilzomib and dexamethasone significantly improved PFS in patients with relapsed/refractory multiple myeloma versus carfilzomib and dexamethasone alone.
Interim results from the phase 3 SUCCESSOR-2 trial demonstrate that mezigdomide plus carfilzomib and dexamethasone significantly improved PFS in patients with relapsed/refractory multiple myeloma versus carfilzomib and dexamethasone alone.
Interim results from the phase 3...
03/11/2026
Oncology
FDA Approval
FDA Approves Teclistamab Plus Daratumumab Hyaluronidase for Relapsed or Refractory Multiple Myeloma
03/05/2026
Emily Estrada
Based on results from the phase 3 MajesTEC-3 trial, the FDA approved teclistamab plus daratumumab hyaluronidase for previously treated patients with relapsed or refractory multiple myeloma.
Based on results from the phase 3 MajesTEC-3 trial, the FDA approved teclistamab plus daratumumab hyaluronidase for previously treated patients with relapsed or refractory multiple myeloma.
Based on results from the phase...
03/05/2026
Oncology
News
FDA Issues Draft Guidance on Use of MRD and Complete Response as End Points to Support Accelerated Approval in Multiple Myeloma
01/20/2026
Emily Estrada
On January 20, 2026, the FDA issued guidance outlining recommendations for the use of minimal residual disease and complete response as primary end points to support accelerated approval of drugs and biologics for the treatment of multiple...
On January 20, 2026, the FDA issued guidance outlining recommendations for the use of minimal residual disease and complete response as primary end points to support accelerated approval of drugs and biologics for the treatment of multiple...
On January 20, 2026, the FDA...
01/20/2026
Oncology
News
Oral Iberdomide Combination Demonstrates Clinically Meaningful Activity for R/R Multiple Myeloma
01/14/2026
Emily Estrada
The all-oral combination of iberdomide, cyclophosphamide, and dexamethasone (IberCd) demonstrated a median progression-free survival and manageable safety in patients with R/R multiple myeloma previously exposed to multiple drug classes.
The all-oral combination of iberdomide, cyclophosphamide, and dexamethasone (IberCd) demonstrated a median progression-free survival and manageable safety in patients with R/R multiple myeloma previously exposed to multiple drug classes.
The all-oral combination of...
01/14/2026
Oncology
Conference Coverage
Belantamab Mafodotin Triplet for R/R MM Shows Sustained Superiority vs Pomalidomide, Bortezomib, and Dexamethasone: DREAMM-8 Long-Term Follow-Up
12/07/2025
Gina Tomaine
Deep responses and durable outcomes were demonstrated among patients treated with belantamab mafodotin plus pomalidomide and dexamethasone from long-term follow-up of the phase 3 DREAMM-8 study presented at the 2025 ASH Annual Meeting.
Deep responses and durable outcomes were demonstrated among patients treated with belantamab mafodotin plus pomalidomide and dexamethasone from long-term follow-up of the phase 3 DREAMM-8 study presented at the 2025 ASH Annual Meeting.
Deep responses and durable...
12/07/2025
Oncology
Conference Coverage
Outcomes of Cilta-Cel Manufacturing for Lenalidomide-Refractory Multiple Myeloma Strongly Influenced by Prior Lines of Therapy
12/06/2025
Emily Estrada
The success of ciltacabtagene autoleucel manufacturing for patients with lenalidomide-refractory MM as early as first relapse decreases with more prior lines of therapy, according to data presented at the 2025 ASH Annual Meeting & Exposition.
The success of ciltacabtagene autoleucel manufacturing for patients with lenalidomide-refractory MM as early as first relapse decreases with more prior lines of therapy, according to data presented at the 2025 ASH Annual Meeting & Exposition.
The success of ciltacabtagene...
12/06/2025
Oncology
Conference Coverage
Talquetamab Plus Teclistamab Demonstrates Durable Efficacy for Patients With R/R MM and Extramedullary Disease: Updated Results from RedirecTT-1 Study
12/06/2025
Emily Estrada
Talquetamab plus teclistamab achieved high response rates for patients with relapsed/refractory multiple myeloma and true extramedullary disease, according to longer follow-up, phase 2 results presented at the 2025 ASH Annual Meeting &...
Talquetamab plus teclistamab achieved high response rates for patients with relapsed/refractory multiple myeloma and true extramedullary disease, according to longer follow-up, phase 2 results presented at the 2025 ASH Annual Meeting &...
Talquetamab plus teclistamab...
12/06/2025
Oncology
Conference Coverage
Identifying Key Predictors of Early Relapse After Treatment With Ciltacabtagene Autoleucel to Inform Risk-Adapted Strategies for Patients With R/R MM
12/06/2025
Emily Estrada
A multicenter analysis presented at the 2025 ASH Annual Meeting identified key predictors of relapse within 18 months of ciltacabtagene autoleucel infusion to improve treatment strategy for patients with high-risk relapsed/refractory multiple...
A multicenter analysis presented at the 2025 ASH Annual Meeting identified key predictors of relapse within 18 months of ciltacabtagene autoleucel infusion to improve treatment strategy for patients with high-risk relapsed/refractory multiple...
A multicenter analysis presented...
12/06/2025
Oncology
Conference Coverage
Cilta-Cel Demonstrates Deep and Durable Responses for Standard-Risk Relapsed/Refractory Myeloma: CARTITUDE-4 Subgroup Analysis
12/06/2025
Emily Estrada
Based on results from the CARTITUDE-4 study presented at the 2025 ASH Annual Meeting, a ciltacabtagene autoleucel infusion achieved durable responses and promising survival outcomes for standard-risk relapsed/refractory multiple myeloma.
Based on results from the CARTITUDE-4 study presented at the 2025 ASH Annual Meeting, a ciltacabtagene autoleucel infusion achieved durable responses and promising survival outcomes for standard-risk relapsed/refractory multiple myeloma.
Based on results from the...
12/06/2025
Oncology
Joshua Richter, MD
Conference Coverage
Addressing Disparities in CAR-T Access in Treating Multiple Myeloma
12/01/2025
Joshua Richter, MD
Joshua Richter, MD, shares details on the long-term efficacy of CAR T-cell therapy for patients with multiple myeloma and highlights the need for expanded, equitable access for all patients at the 2025 Lymphoma, Leukemia & Myeloma Congress.
Joshua Richter, MD, shares details on the long-term efficacy of CAR T-cell therapy for patients with multiple myeloma and highlights the need for expanded, equitable access for all patients at the 2025 Lymphoma, Leukemia & Myeloma Congress.
Joshua Richter, MD, shares...
12/01/2025
Oncology

Interactive Features

Quiz
Oral Iberdomide Combination for R/R MM
02/24/2026
Test your knowledge on the safety profile of oral iberdomide plus low-dose cyclophosphamide and dexamethasone for patents with R/R multiple myeloma.
Test your knowledge on the safety profile of oral iberdomide plus low-dose cyclophosphamide and dexamethasone for patents with R/R multiple myeloma.
Test your knowledge on the...
02/24/2026
Oncology
Quiz
Daratumumab for High-Risk Smoldering Multiple Myeloma
10/30/2025
Emily Estrada
True or False: According to results from the phase 3 AQUILA study, fixed-duration subcutaneous daratumumab significantly prolonged PFS and delayed treatment initiation compared with active monitoring for patients with high-risk smoldering MM.
True or False: According to results from the phase 3 AQUILA study, fixed-duration subcutaneous daratumumab significantly prolonged PFS and delayed treatment initiation compared with active monitoring for patients with high-risk smoldering MM.
True or False: According to...
10/30/2025
Oncology
Quiz
Clarithromycin-Based Quadruplet Therapy for R/R MM
10/24/2025
True or False: For patients with R/R multiple myeloma, including those with high-risk cytogenetics, an all-oral combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated high response rates and prolonged...
True or False: For patients with R/R multiple myeloma, including those with high-risk cytogenetics, an all-oral combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated high response rates and prolonged...
True or False: For patients with...
10/24/2025
Oncology
Quiz
Pomalidomide-Based Regimen for Multiple Myeloma Treatment
09/19/2025
True or False: For patients with first-relapsed multiple myeloma, the addition of pomalidomide to bortezomib and dexamethasone demonstrated a significantly worse progression-free survival and overall response rate compared with control...
True or False: For patients with first-relapsed multiple myeloma, the addition of pomalidomide to bortezomib and dexamethasone demonstrated a significantly worse progression-free survival and overall response rate compared with control...
True or False: For patients with...
09/19/2025
Oncology
Quiz
Venetoclax Plus Bortezomib and Dexamethasone Therapy for R/R MM
08/04/2025
In the phase 3 BELLINI clinical trial, patients with R/R multiple myeloma who received venetoclax combined with bortezomib and dexamethasone demonstrated what median PFS compared to treatment with a placebo?
In the phase 3 BELLINI clinical trial, patients with R/R multiple myeloma who received venetoclax combined with bortezomib and dexamethasone demonstrated what median PFS compared to treatment with a placebo?
In the phase 3 BELLINI clinical...
08/04/2025
Oncology
Quiz
Belantamab Mafodotin Combination for R/R Multiple Myeloma
07/17/2025
In the DREAMM-8 trial, patients with multiple myeloma treated with belantamab mafodotin, pomalidomide, and dexamethasone demonstrated what median PFS compared to those receiving pomalidomide, bortezomib, and dexamethasone?
In the DREAMM-8 trial, patients with multiple myeloma treated with belantamab mafodotin, pomalidomide, and dexamethasone demonstrated what median PFS compared to those receiving pomalidomide, bortezomib, and dexamethasone?
In the DREAMM-8 trial, patients...
07/17/2025
Oncology
Quiz
Triplet Regimen for Relapsed/Refractory Multiple Myeloma
06/16/2025
What was the most common grade ≥ 3 adverse event associated with a weekly triplet regimen of carfilzomib, cyclophosphamide, and dexamethasone for patients with relapsed/refractory multiple myeloma?
What was the most common grade ≥ 3 adverse event associated with a weekly triplet regimen of carfilzomib, cyclophosphamide, and dexamethasone for patients with relapsed/refractory multiple myeloma?
What was the most common grade ≥...
06/16/2025
Oncology
Quiz
Anti-GPRC5D CAR T-Cell Therapy for Relapsed/Refractory MM
05/01/2025
According to a systematic review and meta-analysis, what proportion of patients with MM treated with anti-GPRC5D CAR T-cell therapy achieved complete response?
According to a systematic review and meta-analysis, what proportion of patients with MM treated with anti-GPRC5D CAR T-cell therapy achieved complete response?
According to a systematic review...
05/01/2025
Oncology
Quiz
GPRC5D-Targeted CAR T-Cell Therapy for Multiple Myeloma
04/02/2025
What was the reported hematologic toxicity profile of GPRC5D-targeted CAR T-cell therapy among patients with multiple myeloma?
What was the reported hematologic toxicity profile of GPRC5D-targeted CAR T-cell therapy among patients with multiple myeloma?
What was the reported...
04/02/2025
Oncology
Quiz
Weekly Combination Therapy for Patients With R/R Multiple Myeloma
07/11/2024
07/11/2024
Oncology

Recent News

News
Mezigdomide Plus Carfilzomib and Dexamethasone Improves PFS in R/R Multiple Myeloma
03/11/2026
Stephanie Holland
Interim results from the phase 3 SUCCESSOR-2 trial demonstrate that mezigdomide plus carfilzomib and dexamethasone significantly improved PFS in patients with relapsed/refractory multiple myeloma versus carfilzomib and dexamethasone alone.
Interim results from the phase 3 SUCCESSOR-2 trial demonstrate that mezigdomide plus carfilzomib and dexamethasone significantly improved PFS in patients with relapsed/refractory multiple myeloma versus carfilzomib and dexamethasone alone.
Interim results from the phase 3...
03/11/2026
Oncology
FDA Approval
FDA Approves Teclistamab Plus Daratumumab Hyaluronidase for Relapsed or Refractory Multiple Myeloma
03/05/2026
Emily Estrada
Based on results from the phase 3 MajesTEC-3 trial, the FDA approved teclistamab plus daratumumab hyaluronidase for previously treated patients with relapsed or refractory multiple myeloma.
Based on results from the phase 3 MajesTEC-3 trial, the FDA approved teclistamab plus daratumumab hyaluronidase for previously treated patients with relapsed or refractory multiple myeloma.
Based on results from the phase...
03/05/2026
Oncology
News
FDA Issues Draft Guidance on Use of MRD and Complete Response as End Points to Support Accelerated Approval in Multiple Myeloma
01/20/2026
Emily Estrada
On January 20, 2026, the FDA issued guidance outlining recommendations for the use of minimal residual disease and complete response as primary end points to support accelerated approval of drugs and biologics for the treatment of multiple...
On January 20, 2026, the FDA issued guidance outlining recommendations for the use of minimal residual disease and complete response as primary end points to support accelerated approval of drugs and biologics for the treatment of multiple...
On January 20, 2026, the FDA...
01/20/2026
Oncology
News
Oral Iberdomide Combination Demonstrates Clinically Meaningful Activity for R/R Multiple Myeloma
01/14/2026
Emily Estrada
The all-oral combination of iberdomide, cyclophosphamide, and dexamethasone (IberCd) demonstrated a median progression-free survival and manageable safety in patients with R/R multiple myeloma previously exposed to multiple drug classes.
The all-oral combination of iberdomide, cyclophosphamide, and dexamethasone (IberCd) demonstrated a median progression-free survival and manageable safety in patients with R/R multiple myeloma previously exposed to multiple drug classes.
The all-oral combination of...
01/14/2026
Oncology
Conference Coverage
Belantamab Mafodotin Triplet for R/R MM Shows Sustained Superiority vs Pomalidomide, Bortezomib, and Dexamethasone: DREAMM-8 Long-Term Follow-Up
12/07/2025
Gina Tomaine
Deep responses and durable outcomes were demonstrated among patients treated with belantamab mafodotin plus pomalidomide and dexamethasone from long-term follow-up of the phase 3 DREAMM-8 study presented at the 2025 ASH Annual Meeting.
Deep responses and durable outcomes were demonstrated among patients treated with belantamab mafodotin plus pomalidomide and dexamethasone from long-term follow-up of the phase 3 DREAMM-8 study presented at the 2025 ASH Annual Meeting.
Deep responses and durable...
12/07/2025
Oncology
Conference Coverage
Outcomes of Cilta-Cel Manufacturing for Lenalidomide-Refractory Multiple Myeloma Strongly Influenced by Prior Lines of Therapy
12/06/2025
Emily Estrada
The success of ciltacabtagene autoleucel manufacturing for patients with lenalidomide-refractory MM as early as first relapse decreases with more prior lines of therapy, according to data presented at the 2025 ASH Annual Meeting & Exposition.
The success of ciltacabtagene autoleucel manufacturing for patients with lenalidomide-refractory MM as early as first relapse decreases with more prior lines of therapy, according to data presented at the 2025 ASH Annual Meeting & Exposition.
The success of ciltacabtagene...
12/06/2025
Oncology
Conference Coverage
Talquetamab Plus Teclistamab Demonstrates Durable Efficacy for Patients With R/R MM and Extramedullary Disease: Updated Results from RedirecTT-1 Study
12/06/2025
Emily Estrada
Talquetamab plus teclistamab achieved high response rates for patients with relapsed/refractory multiple myeloma and true extramedullary disease, according to longer follow-up, phase 2 results presented at the 2025 ASH Annual Meeting &...
Talquetamab plus teclistamab achieved high response rates for patients with relapsed/refractory multiple myeloma and true extramedullary disease, according to longer follow-up, phase 2 results presented at the 2025 ASH Annual Meeting &...
Talquetamab plus teclistamab...
12/06/2025
Oncology
Conference Coverage
Identifying Key Predictors of Early Relapse After Treatment With Ciltacabtagene Autoleucel to Inform Risk-Adapted Strategies for Patients With R/R MM
12/06/2025
Emily Estrada
A multicenter analysis presented at the 2025 ASH Annual Meeting identified key predictors of relapse within 18 months of ciltacabtagene autoleucel infusion to improve treatment strategy for patients with high-risk relapsed/refractory multiple...
A multicenter analysis presented at the 2025 ASH Annual Meeting identified key predictors of relapse within 18 months of ciltacabtagene autoleucel infusion to improve treatment strategy for patients with high-risk relapsed/refractory multiple...
A multicenter analysis presented...
12/06/2025
Oncology
Conference Coverage
Cilta-Cel Demonstrates Deep and Durable Responses for Standard-Risk Relapsed/Refractory Myeloma: CARTITUDE-4 Subgroup Analysis
12/06/2025
Emily Estrada
Based on results from the CARTITUDE-4 study presented at the 2025 ASH Annual Meeting, a ciltacabtagene autoleucel infusion achieved durable responses and promising survival outcomes for standard-risk relapsed/refractory multiple myeloma.
Based on results from the CARTITUDE-4 study presented at the 2025 ASH Annual Meeting, a ciltacabtagene autoleucel infusion achieved durable responses and promising survival outcomes for standard-risk relapsed/refractory multiple myeloma.
Based on results from the...
12/06/2025
Oncology
News
Clarithromycin-Based Quadruplet Therapy Demonstrates Promising Clinical Responses for Treatment of Relapsed/Refractory Multiple Myeloma
09/24/2025
Emily Estrada
For patients with relapsed/refractory multiple myeloma, the combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated promising clinical efficacy and a manageable safety profile.
For patients with relapsed/refractory multiple myeloma, the combination of clarithromycin, ixazomib, pomalidomide, and dexamethasone demonstrated promising clinical efficacy and a manageable safety profile.
For patients with...
09/24/2025
Oncology
FDA Approval
FDA Approves Nivolumab Plus Doxorubicin, Vinblastine, and Dacarbazine for Previously Untreated Patients With Advanced Classical Hodgkin Lymphoma
03/20/2026
Emily Estrada
Based on results from the SWOG 1826 trial, the FDA has approved nivolumab plus doxorubicin, vinblastine, and dacarbazine for previously untreated patients with advanced classical Hodgkin lymphoma.
Based on results from the SWOG 1826 trial, the FDA has approved nivolumab plus doxorubicin, vinblastine, and dacarbazine for previously untreated patients with advanced classical Hodgkin lymphoma.
Based on results from the SWOG...
03/20/2026
Oncology
News
Botensilimab Plus Balstilimab Demonstrates Promise in Refractory Metastatic Colorectal Cancer
03/18/2026
Emily Estrada
According to a comparative analysis of clinical trial data, botensilimab plus balstilimab provided a promising overall survival benefit in refractory MSS metastatic colorectal cancer.
According to a comparative analysis of clinical trial data, botensilimab plus balstilimab provided a promising overall survival benefit in refractory MSS metastatic colorectal cancer.
According to a comparative...
03/18/2026
Oncology
News
Belzutifan Plus Lenvatinib Improves PFS in Advanced Clear Cell Renal Cell Carcinoma
03/11/2026
Stephanie Holland
Interim results from the phase 3 LITESPARK-011 trial demonstrate that belzutifan plus lenvatinib significantly improved progression-free survival compared with cabozantinib among previously treated patients with advanced clear cell renal cell...
Interim results from the phase 3 LITESPARK-011 trial demonstrate that belzutifan plus lenvatinib significantly improved progression-free survival compared with cabozantinib among previously treated patients with advanced clear cell renal cell...
Interim results from the phase 3...
03/11/2026
Oncology
News
Mezigdomide Plus Carfilzomib and Dexamethasone Improves PFS in R/R Multiple Myeloma
03/11/2026
Stephanie Holland
Interim results from the phase 3 SUCCESSOR-2 trial demonstrate that mezigdomide plus carfilzomib and dexamethasone significantly improved PFS in patients with relapsed/refractory multiple myeloma versus carfilzomib and dexamethasone alone.
Interim results from the phase 3 SUCCESSOR-2 trial demonstrate that mezigdomide plus carfilzomib and dexamethasone significantly improved PFS in patients with relapsed/refractory multiple myeloma versus carfilzomib and dexamethasone alone.
Interim results from the phase 3...
03/11/2026
Oncology
News
FDA Approves Piflufolastat F 18 Injection for the Detection of PSMA-Positivity Among Patients With Prostate Cancer
03/11/2026
Stephanie Holland
Based on results from the OSPREY and CONDOR trials, the FDA has approved piflufolastat F 18 injection for the detection of PSMA-positive lesions in patients with prostate cancer.
Based on results from the OSPREY and CONDOR trials, the FDA has approved piflufolastat F 18 injection for the detection of PSMA-positive lesions in patients with prostate cancer.
Based on results from the OSPREY...
03/11/2026
Radiopharmaceutical Education Institute
FDA Alerts
Ipsen Voluntarily Withdraws Tazemetostat Following Updated Safety Findings from the SYMPHONY-1 Trial
03/11/2026
Stephanie Holland
Based on emerging safety data from the ongoing SYMPHONY-1 trial, Ipsen has voluntarily withdrawn tazemetostat across all approved indications.
Based on emerging safety data from the ongoing SYMPHONY-1 trial, Ipsen has voluntarily withdrawn tazemetostat across all approved indications.
Based on emerging safety data...
03/11/2026
Oncology
News
Pimicotinib Maintains Favorable Safety Profile in Tenosynovial Giant Cell Tumor
03/11/2026
Stephanie Holland
Updated safety results from the phase 3 MANEUVER trial demonstrate that pimicotinib was associated with manageable and largely reversible adverse events among patients with symptomatic, unresectable tenosynovial giant cell tumor.
Updated safety results from the phase 3 MANEUVER trial demonstrate that pimicotinib was associated with manageable and largely reversible adverse events among patients with symptomatic, unresectable tenosynovial giant cell tumor.
Updated safety results from the...
03/11/2026
Oncology
News
Cemiplimab Improves Disease-Free Survival in High-Risk Cutaneous Squamous Cell Carcinoma
03/05/2026
Stephanie Holland
Results from the phase 3 C-POST trial demonstrated that adjuvant cemiplimab significantly improved disease-free survival compared with placebo among patients with high-risk cSCC.
Results from the phase 3 C-POST trial demonstrated that adjuvant cemiplimab significantly improved disease-free survival compared with placebo among patients with high-risk cSCC.
Results from the phase 3 C-POST...
03/05/2026
Oncology
FDA Approval
FDA Approves Teclistamab Plus Daratumumab Hyaluronidase for Relapsed or Refractory Multiple Myeloma
03/05/2026
Emily Estrada
Based on results from the phase 3 MajesTEC-3 trial, the FDA approved teclistamab plus daratumumab hyaluronidase for previously treated patients with relapsed or refractory multiple myeloma.
Based on results from the phase 3 MajesTEC-3 trial, the FDA approved teclistamab plus daratumumab hyaluronidase for previously treated patients with relapsed or refractory multiple myeloma.
Based on results from the phase...
03/05/2026
Oncology
News
Tokyo-172 BCG is Noninferior to TICE BCG in High-Risk Non-Muscle Invasive Bladder Cancer
03/04/2026
Emily Estrada
Results from the SWOG S162 study demonstrated that Tokyo-172 BCG was noninferior to TICE BCG in patients with high-risk non-muscle invasive bladder cancer.
Results from the SWOG S162 study demonstrated that Tokyo-172 BCG was noninferior to TICE BCG in patients with high-risk non-muscle invasive bladder cancer.
Results from the SWOG S162 study...
03/04/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use